Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Gina Mazzariello Sells 8,828 Shares of Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 8,828 shares of the company’s stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $14.58, for a total value of $128,712.24. Following the transaction, the insider owned 148,141 shares of the company’s stock, valued at approximately $2,159,895.78. This represents a 5.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amylyx Pharmaceuticals Stock Down 5.1%

Shares of Amylyx Pharmaceuticals stock opened at $13.29 on Friday. The company has a market cap of $1.19 billion, a PE ratio of -5.32 and a beta of -0.34. The business has a 50 day moving average of $10.19 and a 200 day moving average of $6.93. Amylyx Pharmaceuticals, Inc. has a 52 week low of $2.60 and a 52 week high of $15.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.02). On average, research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on AMLX shares. Wall Street Zen raised Amylyx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, July 18th. Bank of America upped their price target on Amylyx Pharmaceuticals from $10.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. The Goldman Sachs Group upped their price target on Amylyx Pharmaceuticals from $10.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, September 16th. Jefferies Financial Group started coverage on Amylyx Pharmaceuticals in a research note on Tuesday, June 24th. They issued a “hold” rating on the stock. Finally, Citigroup began coverage on Amylyx Pharmaceuticals in a research note on Tuesday, June 17th. They issued a “buy” rating and a $12.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $14.50.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of institutional investors have recently modified their holdings of AMLX. California State Teachers Retirement System purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth $28,000. Valeo Financial Advisors LLC purchased a new stake in shares of Amylyx Pharmaceuticals in the first quarter worth $35,000. R Squared Ltd grew its stake in shares of Amylyx Pharmaceuticals by 99.9% in the first quarter. R Squared Ltd now owns 12,736 shares of the company’s stock worth $45,000 after acquiring an additional 6,366 shares during the last quarter. Ameritas Investment Partners Inc. bought a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at $45,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Amylyx Pharmaceuticals by 433.2% during the second quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after purchasing an additional 5,904 shares in the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.